Hôpital Saint-Louis
Welcome,         Profile    Billing    Logout  
 15 Trials 
23 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
KILADJIAN, Jean-Jacques
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Calendar Jan 2024 - Dec 2024: Approval for myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Feb 2024 - Feb 2024: Exclusivity expiry in US
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
NCT06514807: A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients

Recruiting
3
117
Europe, RoW
Ropeginterferon alfa-2b (BESREMi®)
AOP Orphan Pharmaceuticals AG
Essential Thrombocythaemia
03/28
03/28
MITHRIDATE, NCT04116502: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera

Recruiting
3
586
Europe
Ruxolitinib, Jakavi®, Hydroxycarbamide, Hydroxyurea, Interferon-Alpha, Interferon, alpha interferon, Intron® A, Roferon® A
University of Birmingham, Novartis, MPN Voice, French National Cancer Institute (Institut National Du Cancer - France)
Polycythemia Vera
10/28
04/30
AVAJAK, NCT05198960: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

Recruiting
3
1308
Europe
Direct Oral Anticoagulants, Low-dose aspirin
University Hospital, Brest
Polycythemia Vera, Essential Thrombocythemia, Prefibrotic/Early Primary Myelofibrosis, JAK2 V617F, High-risk Patients
07/27
07/27
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis

Hourglass Jul 2023 - Dec 2023 : Top-line data from XPORT-MF-035 trial for myelofibrosis
Checkmark First patient dosed as a monotherapy in patients with 2L myelofibrosis
Dec 2021 - Dec 2021: First patient dosed as a monotherapy in patients with 2L myelofibrosis
Active, not recruiting
2
112
Europe, US, RoW
Selinexor, Physician's Choice Treatment
Karyopharm Therapeutics Inc
Myelofibrosis
01/25
01/25
MPN-COVID, NCT04385160: Myeloproliferative Neoplasms (MPN) and COVID-19

Recruiting
N/A
552
Europe, US, RoW
Fondazione per la Ricerca Ospedale Maggiore, European Leukemia Net
Myeloproliferative Neoplasm, COVID
02/22
08/22
Rea, Delphine
ACTIW, NCT02767063: Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR

Recruiting
1/2
100
Europe
Pioglitazone, Avelumab
Versailles Hospital
Leukemia, Myeloid, Chronic-Phase
11/22
06/23
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Active, not recruiting
1/2
122
Europe, US, RoW
Vodobatinib (K0706) capsules
Sun Pharma Advanced Research Company Limited
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
08/26
08/26
EPIK, NCT03481868: EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors

Recruiting
N/A
160
Europe
Collection of blood and bone marrow
University Hospital, Clermont-Ferrand, Institut Paoli-Calmettes, CHRU Lille, hematology department, CH Annecy Genevois, Institut Bergonié Bordeaux, hematology department, CHU Nancy, hematology department, CHU Saint-Etienne, hematology department, Institut Universitaire du Cancer de Toulouse - Oncopole, hematology department, CHU Caen, hematology department, CHU Nice, hematology department, CHU Lyon, hematology department, AP-HP, hematology department, AP-HP Hôpital Henri-Mondor, hematology department, Versailles Hospital, Centre Leon Berard, University Hospital, Grenoble
Chronic Myeloid Leukemia (CML), Chronic Phase
05/25
02/26
Bergeron-Lafaurie, Anne
FORMULA-OLS, NCT03583164 / 2017-001290-17: Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options

Completed
2
203
Europe, US, RoW
Olorofim, F901318
F2G Biotech GmbH, Iqvia Pty Ltd
Invasive Fungal Infections
02/23
02/23
Proglegio, NCT03064737: Bacterial and Human Biomarkers of Prognostic Value for Severe Legionnaire's Disease

Recruiting
N/A
300
Europe
Skin biopsy for genetic analyze
Hospices Civils de Lyon
Legionella
01/24
01/25
Doucet, Ludovic
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
Optim-UCPVax, NCT04263051: Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer

Active, not recruiting
2
111
Europe
UCPVax + Nivolumab, standard chemotherapy
Centre Hospitalier Universitaire de Besancon, Bristol-Myers Squibb, Fondation ARC
Advanced Non-small Cell Lung Cancer
09/23
09/25
PersoMed-I, NCT04402073 / 2020-003063-26: Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma

Active, not recruiting
2
20
Europe, RoW
Sonidegib, Cisplatin, Lomustine, Vincristine, radiotherapy
European Organisation for Research and Treatment of Cancer - EORTC, EORTC-BTG, Sunpharmaceuticals
Medulloblastoma
04/25
04/25
TNG908-C101, NCT05275478: Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Active, not recruiting
1/2
192
Europe, US
TNG908
Tango Therapeutics, Inc.
Locally Advanced Solid Tumor
04/25
09/25
Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Recruiting
1/2
374
Europe, Canada, Japan, US, RoW
Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil
Takeda, Takeda Development Center Americas, Inc. (TDC Americas)
Solid Neoplasms
01/26
01/26
Lebbé, Céleste
OPTISARC, NCT05272358: Economic Evaluation of Sarcoma Patients Management in France

Recruiting
N/A
2431
Europe
NETSARC network
Centre Leon Berard, École nationale supérieure des Mines Saint-Etienne France, Rennes University Hospital, Assistance Publique - Hôpitaux de Paris
Sarcoma
06/22
02/24
Verner, Emma
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
300
Europe, RoW
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
12/25
12/28
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
COALITION, NCT04914741: A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)

Active, not recruiting
1/2
80
RoW
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Glofitamab, RO7082859, CD20-TCB, Polatuzumab vedotin
Peter MacCallum Cancer Centre, Australia, Hoffmann-La Roche
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
12/23
07/25
Judet, Alexandra
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
GLORIFY, NCT06186648: Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome

Recruiting
2
40
Europe
Glofitamab + Obinutuzumab
French Innovative Leukemia Organisation, Hoffmann-La Roche
Richter Syndrome
03/26
03/27
Zin, Jean i Marc
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27

Download Options